Publications for all Oxford Principal Investigators within the CAMS Oxford Institute are included here, please use the search functions for publications related to specific Principal Investigators.
A high-throughput two-cell assay for interrogating inhibitory signaling pathways in T cells.
Journal article
Sharma S. et al, (2024), Life Sci Alliance, 7
Group A Streptococcus induces CD1a-autoreactive T cells and promotes psoriatic inflammation.
Journal article
Chen Y-L. et al, (2023), Science immunology, 8
Evaluation of perturbed iron-homeostasis in a prospective cohort of patients with COVID-19.
Journal article
Frost JN. et al, (2022), Wellcome open research, 7
Re-evaluation of human BDCA-2+ DC during acute sterile skin inflammation
Journal article
Chen Y-L. et al, (2020), The Journal of Experimental Medicine, 217
Resistance to apoptosis underpins the corticosteroid insensitivity of group 2 innate lymphoid cells.
Journal article
Luo J. et al, (2019), The Journal of allergy and clinical immunology, 144, 1722 - 1726.e10
Proof-of-concept clinical trial of etokimab shows a key role for IL-33 in atopic dermatitis pathogenesis
Journal article
Chen Y-L. et al, (2019), Science Translational Medicine, 11, eaax2945 - eaax2945
Fevipiprant, a selective prostaglandin D2 receptor 2 antagonist, inhibits human group 2 innate lymphoid cell aggregation and function.
Journal article
Hardman C. et al, (2019), The Journal of allergy and clinical immunology, 143, 2329 - 2333
CD1a presentation of endogenous antigens by group 2 innate lymphoid cells
Journal article
Hardman CS. et al, (2017), Science Immunology, 2, eaan5918 - eaan5918
Phosphodiesterase 4B negatively regulates endotoxin-activated interleukin-1 receptor antagonist responses in macrophages.
Journal article
Yang J-X. et al, (2017), Scientific reports, 7
Psoriatic T cells recognize neolipid antigens generated by mast cell phospholipase delivered by exosomes and presented by CD1a
Journal article
Cheung KL. et al, (2016), Journal of Experimental Medicine, 213, 2399 - 2412
STAT2/IRF9 directs a prolonged ISGF3-like transcriptional response and antiviral activity in the absence of STAT1.
Journal article
Blaszczyk K. et al, (2015), The Biochemical journal, 466, 511 - 524